Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Signs of Puberty01:27

Signs of Puberty

Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

POCUS in pediatric arrest (Res-US pulse check): development and evaluation of a simulation-based curriculum.

Resuscitation plus·2026
Same author

Acute and longitudinal magnetic resonance imaging abnormalities in antibody-mediated encephalitis.

Brain communications·2026
Same author

Plasma proteome in LGI-1 autoimmune encephalitis.

Journal of neuroinflammation·2026
Same author

Reflex lymphocyte subset enumeration for infants with lymphopenia as a surrogate screening tool for severe combined immunodeficiency: a single-centre experience.

Pathology·2026
Same author

Markedly Low Prevalence of Fatty Liver Despite Obesity in Prader-Willi Syndrome: A Search for Protective Genetic Markers.

Journal of clinical and experimental hepatology·2026
Same author

Flow cytometric assessment of measurable residual disease in acute myeloid leukaemia: a summary of current Australasian practice and future directions.

Internal medicine journal·2026

Related Experiment Video

Updated: May 14, 2026

Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays
08:06

Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays

Published on: November 10, 2016

Triptorelin depot stimulation test for central precocious puberty.

David Strich, Noa Kvatinsky, Harry J Hirsch

    Journal of Pediatric Endocrinology & Metabolism : JPEM
    |February 22, 2013
    PubMed
    Summary
    This summary is machine-generated.

    Measuring luteinizing hormone (LH) 60 minutes after depot triptorelin injections can effectively monitor treatment efficacy in central precocious puberty. This method helps determine appropriate therapeutic levels for patients.

    More Related Videos

    Online Transcranial Magnetic Stimulation Protocol for Measuring Cortical Physiology Associated with Response Inhibition
    08:55

    Online Transcranial Magnetic Stimulation Protocol for Measuring Cortical Physiology Associated with Response Inhibition

    Published on: February 8, 2018

    Related Experiment Videos

    Last Updated: May 14, 2026

    Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays
    08:06

    Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays

    Published on: November 10, 2016

    Online Transcranial Magnetic Stimulation Protocol for Measuring Cortical Physiology Associated with Response Inhibition
    08:55

    Online Transcranial Magnetic Stimulation Protocol for Measuring Cortical Physiology Associated with Response Inhibition

    Published on: February 8, 2018

    Area of Science:

    • Pediatric Endocrinology
    • Reproductive Medicine
    • Pharmacology

    Background:

    • Monitoring therapeutic efficacy of depot leuprolide acetate in central precocious puberty relies on acute gonadotropin responses.
    • Such monitoring for depot triptorelin, another GnRH agonist, has not been previously documented.

    Purpose of the Study:

    • To evaluate the utility of gonadotropin levels measured after therapeutic depot triptorelin injections for assessing treatment effectiveness.

    Main Methods:

    • Thirty-two patients (29 girls, 3 boys) with central precocious puberty received triptorelin depot (3.75 mg).
    • Blood samples were collected pre-injection and at 30 min to 2 h post-injection.
    • Retrospective analysis of clinical data and hormone levels was performed.

    Main Results:

    • Following the initial injection, mean 60-minute LH was 21.6±18.0 IU/L and FSH was 13.5±3.6 IU/L.
    • In patients achieving clinical suppression, post-injection LH and FSH levels were within 2.1 and 3.6 IU/L above the mean, respectively.
    • Two patients with insufficient suppression exhibited LH levels at or above these defined limits.

    Conclusions:

    • Sixty-minute post-injection luteinizing hormone (LH) levels after depot triptorelin administration are a reliable indicator of treatment efficacy.
    • Established thresholds for suppressed LH levels can be used to assess treatment adequacy.